Subscribe To
AGEN / Agenus: Advancement Of Botensilimab Could Create A Great Pivot Point
AGEN News
By Seeking Alpha
October 6, 2023
Agenus: Getting The Tough Decisions Right With Catalysts Ahead
AGEN has chosen to focus its efforts on botensilimab and balstilimab, postponing its other clinical and preclinical programs. A 25% workforce reductio more_horizontal
By Zacks Investment Research
August 8, 2023
Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Agenus (AGEN) give a sense of how the business performed in the quarter ended June 2023, it could be worth more_horizontal
By Proactive Investors
June 6, 2023
Agenus is “turning cold tumors hot and making CTLA-4 cool again”
Agenus Inc (NASDAQ:AGEN) and its optimized approach on a validated mechanism (CTLA-4) offer a rare investible opportunity in immuno-oncology (IO), wro more_horizontal
By Seeking Alpha
June 5, 2023
Agenus: This Time May Be Different
Agenus Inc. has existed for a long three decades, doing nothing much really. They have been producing very strong data from botensilimab lately. Agenu more_horizontal
By The Motley Fool
March 23, 2023
Why Agenus Stock Is Slumping This Week
Agenus stock has been trending lower ever since the company reported 2022 Q4 earnings last week. Investors appear to be concerned about a possible cap more_horizontal
By PennyStocks
March 17, 2023
Penny Stocks To Buy Now: 7 To Watch Before Next Week
Are these penny stocks to buy now or avoid entirely? The post Penny Stocks To Buy Now: 7 To Watch Before Next Week appeared first on Penny Stocks to B more_horizontal
By GlobeNewsWire
March 12, 2023
Agenus Cancels Conference Call to Discuss the Company's Minority Cash Holdings at SVB in Light of Government's SVB Deposit Access Announcement
Conference Call Cancelled Conference Call Cancelled more_horizontal
By GlobeNewsWire
March 11, 2023
Agenus Schedules Conference Call to Discuss the Company's Minority Cash Holdings at SVB
Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET more_horizontal